Pfizer, Novo Nordisk and Metsera
Digest more
Here's what's happening for Pfizer right now, and why investors still might want to take the long view with this high-yield stock. In some ways, the pharmaceutical industry is pretty simple: You ...
Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...
The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...
Concerns about the company's future growth are likely keeping investors away.
Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...
Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...
The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate ...
Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School ...
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
14don MSNOpinion
Should You Buy Pfizer Stock Before Nov. 4?
Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback